Circulating levels of stress associated peptide Urocortin in heart failure patients

Peptides

Volumn 31, Issue 2, 2010, Pages 354-356

  Gruson, D ^a   Ahn, S A ^a   Ketelslegers, J M ^a   Rousseau, M F ^a  

^a CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR DERIVATIVE; BIG ENDOTHELIN 1; BIOLOGICAL MARKER; NEUROHORMONE; UROCORTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEART FAILURE; HEART PROTECTION; HORMONE RESPONSE; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; STRESS;

AGED; AGING; ATRIAL NATRIURETIC FACTOR; ENDOTHELIN-1; GLOMERULAR FILTRATION RATE; HEART FAILURE; HUMANS; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; UROCORTINS;

EID: 73949159642     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2009.11.023     Document Type: Article

References (20)

1. Boonprasert P., Lailerd N., and Chattipakorn N. Urocortins in heart failure and ischemic heart disease. Int J Cardiol 127 (2008) 307-312
2. Brar B.K., Stephanou A., Knight R., and Latchman D.S. Activation of protein kinase B/Akt by urocortin is essential for its ability to protect cardiac cells against hypoxia/reoxygenation-induced cell death. J Mol Cell Cardiol 34 (2002) 483-492
3. Burnett Jr. J.C. Urocortin: advancing the neurohumoral hypothesis of heart failure. Circulation 112 (2005) 3544-3546
4. Charles C.J., Rademaker M.T., Richards A.M., and Yandle T.G. Plasma urocortin 1 in sheep: regional sampling and effects of experimental heart failure. Peptides 27 (2006) 1801-1805
5. Dautzenberg F.M., and Hauger R.L. The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23 (2002) 71-77
6. Davis M.E., Pemberton C.J., Yandle T.G., Fisher S.F., Lainchbury J.G., Frampton C.M., et al. Urocortin 2 infusion in human heart failure. Eur Heart J 28 (2007) 2589-2597
7. Donaldson C.J., Sutton S.W., Perrin M.H., Corrigan A.Z., Lewis K.A., Rivier J.E., et al. Cloning and characterization of human urocortin. Endocrinology 137 (1996) 2167-2170
8. Florio P., Reis F.M., Torres P.B., Calonaci F., Toti P., Bocchi C., et al. Plasma urocortin levels in the diagnosis of ovarian endometriosis. Obstet Gynecol 110 (2007) 594-600
9. Francis G.S., Benedict C., Johnstone D.E., Kirlin P.C., Nicklas J., Liang C.S., et al. Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure. A substudy of the studies of left ventricular dysfunction (SOLVD). Circulation 82 (1990) 1724-1729
10. Goetze J.P. Biochemistry of pro-B-type natriuretic peptide-derived peptides: the endocrine heart revisited. Clin Chem 50 (2004) 1503-1510
11. Gruson D., Rousseau M.F., Ahn S., Van L.F., Thys F., Ketelslegers J.M., and Verschuren F. Accuracy of N-terminal-pro-atrial natriuretic peptide in patients admitted to emergency department. Scand J Clin Lab Invest 68 (2008) 410-414
12. Lawrence K.M., Townsend P.A., Davidson S.M., Carroll C.J., Eaton S., Hubank M., et al. The cardioprotective effect of urocortin during ischaemia/reperfusion involves the prevention of mitochondrial damage. Biochem Biophys Res Commun 321 (2004) 479-486
13. Ng L.L., Loke I.W., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urocortin in human systolic heart failure. Clin Sci (Lond) 106 (2004) 383-388
14. Omland T., Aakvaag A., Bonarjee V.V., Caidahl K., Lie R.T., Nilsen D.W., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93 (1996) 1963-1969
15. Rademaker M.T., Charles C.J., Espiner E.A., Fisher S., Frampton C.M., Kirkpatrick C.M., et al. Beneficial hemodynamic, endocrine, and renal effects of urocortin in experimental heart failure: comparison with normal sheep. J Am Coll Cardiol 40 (2002) 1495-1505
16. Rademaker M.T., Charles C.J., Espiner E.A., Frampton C.M., Lainchbury J.G., and Richards A.M. Four-day urocortin-I administration has sustained beneficial haemodynamic, hormonal, and renal effects in experimental heart failure. Eur Heart J 26 (2005) 2055-2062
17. Richards A.M., Nicholls M.G., Yandle T.G., Frampton C., Espiner E.A., Turner J.G., et al. Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: new neurohormonal predictors of left ventricular function and prognosis after myocardial infarction. Circulation 97 (1998) 1921-1929 %19
18. Van B.R., Gurne O., Selvais P.L., Ahn S.A., Robert A.R., Ketelslegers J.M., et al. Superiority of big endothelin-1 and endothelin-1 over natriuretic peptides in predicting survival in severe congestive heart failure: a 7-year follow-up study. J Card Fail 10 (2004) 490-495
19. Vaughan J., Donaldson C., Bittencourt J., Perrin M.H., Lewis K., Sutton S., et al. Urocortin, a mammalian neuropeptide related to fish urotensin I and to corticotropin-releasing factor. Nature 378 (1995) 287-292
20. Wright S.P., Doughty R.N., Frampton C.M., Gamble G.D., Yandle T.G., and Richards A.M. Plasma urocortin 1 in human heart failure. Circ Heart Fail 2 (2009) 465-471